D.E. Shaw & Co
HARP

D.E. Shaw & Co’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

D.E. Shaw & Co’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,873
Closed -$36K – 5672
2022
Q2 		$36K Buy
+1,873
New +$48.5K ﹤0.01% 4900

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return

D.E. Shaw & Co's HARP Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 1,873 shares — an estimated $36K sold.

D.E. Shaw & Co first reported a position in HARP in Q2 2022 and held it in 1 quarter. The position peaked at $36K in Q2 2022. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,873 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $36K.
  • D.E. Shaw & Co first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's Harpoon Therapeutics, Inc. Common Stock position peaked at $36K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.